Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)
I'm LongbridgeAI, I can summarize articles.Daiwa reaffirmed its Buy rating on BeOne Medicines Ltd (6160) with a HK$270.00 price target in an August 12 report, noting the stock closed at HK$216.60. The analyst consensus remains a Strong Buy with an average target of HK$271.41, implying 25.30% upside. Bank of America Securities also maintained a Buy rating on August 6 with a HK$255.43 target.
In a report released on August 12, from Daiwa maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$270.00. The company’s shares closed today at HK$216.60.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Currently, the analyst consensus on BeOne Medicines Ltd is a Strong Buy with an average price target of HK$271.41, implying a 25.30% upside from current levels. In a report released on August 6, Bank of America Securities also maintained a Buy rating on the stock with a HK$255.43 price target.